Kornimate/medical-research-clean huggingface dataset:
megestrol and exercise in treating patients with cancer-related weight loss

Conditions: Cachexia; Fatigue; Unspecified Adult Solid Tumor, Protocol Specific

Summary: rationale: megestrol helps improve appetite. exercise may decrease cancer-related fatigue, improve strength, and build up lost muscle tissue. exercise plus megestrol may be effective treatment for cancer-related weight loss. purpose: phase ii trial to study the effectiveness of megestrol plus exercise to improve appetite, increase strength, gain lean body tissue, and decrease fatigue in patients who have cancer-related weight loss.

objectives: i. determine the effect of megestrol and progressive resistance training on lean body mass, total body weight, functional capacity, appetite, and fatigue in patients with weight loss due to advanced malignancy. outline: this is a multicenter study. patients receive oral megestrol once daily. patients also begin progressive resistance training 3 days a week. treatment/exercise continues for 12 weeks in the absence of unacceptable toxicity or progressive weight loss (greater than 5 pounds or 5% or more over first 4 study weeks). projected accrual: a total of 46 patients will be accrued for this study within 1 year.

Eligibility criteria:
disease characteristics: advanced nonhormone responsive malignancy (metastatic or incurable) nonvolitional weight loss of between 6-9% of usual body weight over past 6 months or decrease of 5 pounds in the past 2 months or less (not greater than 10% loss of usual body weight) no clinical or radiologic evidence of ascites or pleural effusion no lytic bone metastases patient characteristics: age: over 18 performance status: ecog 0-1 life expectancy: at least 4 months hematopoietic: not specified hepatic: not specified renal: not specified cardiovascular: no venous thrombosis no congestive heart failure other: able to participate in exercise program for 1 hour, 3 times/week no physical handicap that precludes aerobic or resistance exercise no clinical abnormality that renders exercise a risk at least 1 month since strength training of 3 hours or more per week no physical or functional obstruction to food intake no uncontrolled emesis greater than 5 episodes/week no diarrhea greater than 4 stools/day intractable to antidiarrheal medication no iv hyperalimentation no contraindications to megestrol no dementia or mental incompetence no known aids not pregnant or nursing negative pregnancy test prior concurrent therapy: biologic therapy: not specified chemotherapy: not specified endocrine therapy: no concurrent adrenal steroids (other than for replacement), anabolics, appetite stimulants, or progestational agents intermittent corticosteroids as antiemetic or premedication for cancer treatment allowed at least 6 weeks since prior megestrol radiotherapy: not specified surgery: not specified

Keywords: unspecified adult solid tumor, protocol specific fatigue cachexia
testing the effects of rise on eating pathology

Conditions: Eating Disorder Symptoms

Summary: interoception is the process of perceiving one's bodily sensations. interoception is critical for survival and maintaining homeostasis, as it motivates sensation- and need-specific autonomic reflexes and adaptive behaviors (e.g., eating when hungry, terminating eating upon fullness, drinking when thirsty). not all individuals have accurate interoceptive abilities. individuals with eating disorders often have low perception of gastrointestinal, pain, and emotion sensations. interoceptive dysfunction is believed to influence the development and maintenance of many forms of psychopathology. identifying effective ways to restore accurate interoceptive processing is an important aim for clinical researchers. the goal of the present study is to continue to test the effectiveness of a training for interoceptive dysfunction that aims to reconnect individuals with eating disorders with their internal sensations, which is called, reconnecting to internal sensations.

there are individual differences in how well people are able to recognize interoceptive sensations. research supports a role for impaired interoception in the etiology of eating disorders (eds), with the idea being that individuals who are out of touch with hunger and/or satiety are more vulnerable to restrictive and binge eating behaviors, respectively. researchers have connected interoceptive impairment to self-injurious behaviors more broadly, including both direct (i.e., non-suicidal self-injury and suicide attempts) and indirect (i.e., ed behaviors) forms. the investigators have found support for the supposition that impaired interoception-or bodily disconnect-allows people to inflict pain (whether that be through ed behaviors or self-injury) upon themselves, as it is much easier to harm something one is unattached to versus something one cares for. thus, improving interoception (e.g., helping people connect better with their bodies) may improve ed outcomes. this project seeks to test an accessible, online intervention designed to improve interoception and thereby reduce ed symptoms.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of an eating disorder * be a patient at the louisville center for eating disorders * above age 10 exclusion criteria: \*under age 10
a multicenter prospective cohort study on the clinical prognosis of ulcerative colitis

Conditions: Prospective Study; Ulcerative Colitis in Remission

Summary: mucosal healing or histological remission is an important target for the treatment of inflammatory bowel disease. in this study, patients with mucosal healing are defined as a control group, observing their clinical outcomes for 3 years, and describing the recurrence rate. the secondary objective is to study the operative rate, glucocorticoid utilization rate, treatment escalation rate, hospitalization rate and incidence of related complications.

assess the health condition of patients for 1year, 2year,3year and analyze outcomes and complications.

Eligibility criteria:
inclusion criteria: * sign informed consent before proceeding with any specific procedure. * ages:14-75 * subjects were diagnosed with ulcerative colitis in written form. (written diagnosis should include at least one histopathological change). * mucosal healing or histological remission has been achieved after medical treatment. 1. histological assessment is performed by 2 pathologists independently, and endoscopy have been independently evaluated by two endoscopic doctors. 2. prospective cohort study (3) definition of endoscopic mucosal healing: baron score\<=1 and mayo score\<=1 (4) definition of histological remission: truelove/ richards=1 and geboes score\<3.0 (5) sampling methods: the terminal ileum, the ascending colon, the transverse colon, the descending colon, the sigmoid colon, and the rectum, the six parts were randomly taken specimen (at least 2 tissues each). * data integrity: the research data include: 1) enteroscopy; 2) laboratory examination indicators: blood routine, erythrocyte sedimentation rate, c reaction protein, liver function, renal function, fecal calprotectin, 3) serum concentration of infliximab, antibody to infliximab. * subjects were treated with the following treatment mesalazine, glucocorticoid, immunosuppressive agent (azathioprine or thalidomide), biologics (infliximab) 7. subjects have the ability to answer the questionnaire exclusion criteria: * the diagnosis is unclear * subjects with history of colectomy * subjects with history of cancerogenesis * subjects with severe liver disease, defined as child-pugh grade b or grade c * subjects with severe renal disease, defined as estimated glomerular filtration rate\<30 * major cardiovascular events, such as stroke, myocardial infarction, or unstable angina, occurred within 3 months before enrollment. * subjects during pregnancy. * alcohol or drug abuse * poor compliance 10 planners and investors

Keywords: ulcerative colitis mucosal healing histological remission prospective study
compare effects of dressing with honey and eusol

Conditions: Necrotizing Fascitis; Wound Infection

Summary: honey is super saturated solution containing sugar derived from nectar gathered by honeybee. honey is viscus supersaturated solution mainly composed of sugar and water along with minor constituents such as minerals, vitamins, amino acids, organic acids, flavonoids, and other phenolic compound and aromatic substances. honey contents according to percentages are fructose 38.6%, glucose 31%, water 17%, lactose 7.2%, larger sugars 4.7% and rest of micronutrients and elemental compounds are 1.5%. honey enhances wound healing by removing slough and necrotic tissue from wound. it promotes wound healing by increasing angiogenesis, granulation and epithelization. honey possess antimicrobial activity against bacteria like methicillin resistant staphylococcus aureus, vancomycin resistant escherichia coli, pseudomonas aeruginosa, and many other species. it also has activity against some yeast species such as aspergillus and penicillium. honey used for dressing will be 'langnese honey". langnese honey is raw honey / unprocessed packed as collected, quality and quantity will be same for patients.

this prospective randomized trial will be conducted in all patients undergoing dressing after debridement of necrotizing fasciitis wounds. study will be conducted for 6 months after approval irb. patient will be inducted through emergency department. after debridement, patient will be enrolled in study via simple random sampling for dressing with either eusol or honey. honey quantity for wound will be 4ml per square inch. in patient whose both limbs involved by necrotizing fasciitis, after debridement, dressing will be done with honey in one limb and eusol in other limb. patient will be enrolled in study whose debridement already done. eusol is solution commonly used for dressing of wounds. honey is also used for dressing of wounds. honey is a viscous, supersaturated sugar derived from nectar gathered by a honeybee. honey enhances wound healing by providing moist environment, antibacterial activity, deodorizes, decrease inflammation, edema and exudation. honey increase rate of wound healing by promoting angiogenesis, granulation and epithelization. dressing will be done by residents of our ward under supervision of faculty. at first time of debridement pus or tissue will be sent for culture and sensitivity meanwhile broad-spectrum antibiotic will be started. once dressing will started, wide wound span will be measured and assessed daily for granulation tissue and removal of slough. questionnaire will be filled by pi for allergic reaction to solution, appearance of granulation tissue and hospital stay.

Eligibility criteria:
inclusion criteria: * age \>18 years and \<70 years. * necrotizing fasciitis wounds * wide span of wound \<20cm exclusion criteria: * diabetic foot wounds * traumatic wounds
24-hr intraocular pressure (iop) patterns of glaucoma patients after selective laser trabeculoplasty (slt)

Conditions: Glaucoma

Summary: the purpose of this study is to determine the relationship between intraocular pressure (iop) fluctuations of glaucoma patients as recorded with an iop-sensing contact lens (sensimed triggerfish®), during two 24-hour periods after selective laser trabeculoplasty (slt) for routine treatment of glaucoma.


Eligibility criteria:
inclusion criteria: * subjects must correspond to all other inclusion criteria in order to be eligible for the investigation. * subject is able to comply with the study procedures * 18-80 years old * subjects diagnosed with glaucoma, based on presence of repeatable visual field loss and/or glaucomatous optic neuropathy based on masked review of optic disc stereophotographs and under ocular hypotensive treatment, or diagnosed with ocular hypertension, with an iop of \> 22 mmhg at the screening visit and under ocular hypotensive treatment. * subject has consented to be in the trial * visual acuity of 20/200 or better * ability to understand the character and individual consequences of the study * for women of childbearing potential, adequate contraception exclusion criteria: * subjects presenting with any of the following criteria will not be included in the trial: * subjects with contraindications for wearing contact lenses * severe dry eye syndrome * keratoconus or other corneal abnormality * conjunctival or intraocular inflammation * eye surgery prior to and throughout the study. * full frame metal glasses during sensimed triggerfish® monitoring * known hypersensitivity to silicone, plaster or ocular anesthesia (proparacaine) * pregnancy and lactation * simultaneous participation in other clinical studies

Keywords: iop fluctuations during two 24-hour periods
flt pet imaging for cervical cancer

Conditions: Uterine Cervical Neoplasms

Summary: our primary hypothesis is that \[18f\]flt pet can identify active bone marrow in addition to metabolically active tumor. this trial will use flt-pet imaging to define areas of active bone marrow in the pelvis. the radiation plan is then designed to spare that area, in hopes of keeping the bone marrow active during therapy. bone marrow and tumor activity will be monitored using a sequence of flt pet scans during the course of chemotherapy and radiation therapy.

subjects will undergo a total of up to 5 flt pet scans. subjects are randomized between two groups to reduce radiation exposure from the flt pet scans. if bone marrow activity is not identified in one scan, further scans are cancelled until the 1-month follow up scan. this is not a randomization to compare therapeutic efficacy between two study arms. data will be pooled for analysis as pre-specified in the study's statistical plan. group 1 has flt pet scans pretreatment, after 5 radiation treatments, after 10 radiation treatments, after 15 radiation treatments, and then 1 month after completing radiation therapy. group 2 has flt pet scans pretreatment, after 5 radiation treatments, after 10 radiation treatments, after 20 radiation treatments, and then 1 month after completing radiation therapy.

Eligibility criteria:
inclusion criteria: * ability to understand and willingness to sign a written informed consent document. * histologically confirmed stage ib2, iia, iib, iiib, and iva squamous cell carcinoma of the cervix. * scheduled to receive chemo-radiation for oncologic treatment. * karnofsky of at least 60 at time of screening * life expectancy of at least 6 months. * leukocytes at least 3,000/microl * absolute neutrophil count at least 1,500/microl * platelets at least 100,000/microl * total bilirubin at maximum 1.0 mg/dl (uihc limit of normal) * either alt or ast less than 2.5 times the upper limit of normal * creatinine less than 1.5 times the upper limit of normal * non-pregnant, non-nursing, willing to use contraception exclusion criteria: * oncology research protocol requiring full pelvic radiation (i.e., 4-field box technique) or experimental chemotherapy * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with the study requirements. * subjects taking nucleoside analog medications such as those used as antiretroviral agents. * patients who have undergone hysterectomy or will have a hysterectomy as part of their cancer therapy.

Keywords: positron-emission tomography radiotherapy, intensity-modulated
training balance control in children with cerebral palsy using virtual reality games

Conditions: Cerebral Palsy, Spastic

Summary: in this study the clinical relevance of the use of commercially available virtual reality games in the rehabilitation of balance will be assessed in children with cerebral palsy. it will be investigated how different commercially available platforms (i.e. xbox one + kinect and nintendo wii + balance board) will affect the compensations of children with cerebral palsy to preserve their balance. the effect of 1 training session will be assessed as well as the effect of a long-term training of 8 weeks.


Eligibility criteria:
inclusion criteria: 1. children diagnosed with cerebral palsy (spastic type) 2. age: 8-11 years and 11 months 3. bilateral cp (diplegia) \& unilateral cp (hemiplegia) 4. gmfcs level 1 \& 2 5. able to independently stand still for 2 minutes 6. sufficient cooperation to participate in the measurements and training exclusion criteria: 1. no informed consent 2. surgery of the lower limbs that affects mobility 3. botulinum-toxin a treatment within 6 months prior to inclusion in the study 4. vestibular deficits, benign vertigo, adhd or instable epilepsia for typically developing children: inclusion criteria; 1. age: 8-11 years and 11 months 2. no history of neurologic, musculoskeletal or other impairments that could affect mobility

Keywords: balance rehabilitation exergaming virtual reality
study of tocilizumab in combination with methotrexate for treatment of moderate to severe rheumatoid arthritis patients

Conditions: Rheumatoid Arthritis (RA)

Summary: this is a phase iii study to evaluate efficacy and safety of tocilizumab in patients with rheumatoid arthritis.


Eligibility criteria:
inclusion criteria: * patients diagnosed with history of moderate-to- severe rheumatoid arthritis for more than 6 months according to the american college of rheumatology (acr) 1987 revised criteria for the classification of ra. * patients who failed to achieve clinical response to treatment of at least 2 dmards(disease modifying anti-rheumatic drug) (including mtx) for at least 12 weeks within 12 months prior to screening, of which mtx must have been at a stable dose of 10-20 mg/wk for at least 12 weeks prior to screening. all other dmards should be given at standard therapeutic dose. * patients who satisfy swollen joint count (sjc) ≥ 6 (66 joint count) and tender joint count (tjc) ≥ 8 (68 joint count) at screening and baseline. * c-reactive protein (crp) level ≥ 1 mg/dl or an erythrocyte sedimentation rate (esr) ≥ 28 mm/hour at screening and at baseline. exclusion criteria: * patients who have received a major surgery including joint surgery 8 weeks prior to the screening or are scheduled to be operated within 6 months after the enrolment. * patients with rheumatoid autoimmune disease other than ra, including but not limited to sle(system lupus erythematosus), or significant systemic involvement secondary to ra. * patients who belong to the class iv of the acr classification criteria for functional status of ra. (acr amended criteria for the classification of functional capacity in rheumatoid arthritis; class iv: largely or wholly incapacitated with patient bedridden or confined to wheel chair, permitting little or no self-care). * patients with a history of hypersensitivity to human, humanized or murine monoclonal antibodies or patients with contraindication for them. * patients who currently have or have a history of recurrence of bacterial, viral,fungal, or mycobacterial infections or other infectious diseases; tuberculosis(tb),atypical mycobacterial disease, clinically significant granulomatous disease on chest radiograph, hepatitis b, hepatitis c, or herpes zoster and etc. however, a patient with hand \& foot fungal infections can participate.
safety and efficacy study of citalopram and lithium for the treatment of depressive mood disorder symptoms

Conditions: Major Depressive Disorder; Dysthymia; Depression Not Otherwise Specified; Borderline Personality Disorder

Summary: the investigators hypothesize that patients receiving citalopram in combination with lithium will have a greater reduction in depressive symptoms than patients receiving citalopram in combination with placebo.


Eligibility criteria:
inclusion criteria: * 18-75 years of age * meets criteria for major depressive disorder, dysthymia, depression not otherwise specified or borderline personality disorder * ability to speak, read and understand the english language and provide written informed consent exclusion criteria: * current, unstable and significant medical condition or illness * history of thyroid disorder, seizure disorder, tumors or other cns condition that predisposes the patient to risk of seizure * pregnant or lactating females * abnormal clinical laboratory test results * intolerance or hypersensitivity to ssris or lithium * history or current diagnosis of bipolar mood disorder, psychosis, schizophrenia or dementia * certain mediations my not be used prior or during the study

Keywords: hopelessness alone sad troubled depression
multicenter investigation of trabecular micro-bypass stents vs. laser trabeculoplasty

Conditions: Primary Open-Angle Glaucoma

Summary: to evaluate the safety and effectiveness of trabecular micro-bypass stents (two stents per study eye) vs. laser trabeculoplasty, in subjects with open angle glaucoma


Eligibility criteria:
inclusion criteria: * open angle glaucoma exclusion criteria: * active corneal inflammation or edema * choroidal detachment, effusion, choroiditis
an observational study of mircera (methoxy polyethylene glycol-epoetin beta) in patients with chronic kidney disease not on dialysis

Conditions: Kidney Disease, Chronic

Summary: this observational, prospective, multicenter study will describe the mean dose of mircera (methoxy polyethylene glycol-epoetin beta) and the hemoglobin levels in patients with chronic kidney disease. patients are not on dialysis and are naive to, or have received erythropoiesis stimulating agent treatment. data will be collected for 10 months.


Eligibility criteria:
inclusion criteria: * adults patients, \>/=18 years of age * presence of chronic kidney disease (stage 3-4) exclusion criteria: * participation in another clinical study
analgesic efficacy of ultrasound guided paravertebral block in percutaneous nephrolithotomy patients

Conditions: Pain, Postoperative; Anesthesia, Regional

Summary: the aim of this study is to investigate the analgesic effects of thoracal paravertebral block in the patients undergoing percutaneous nephrolitotomy. paravertebral block was applied to the study group. conventional analgesia methods were applied to the control group.

randomization was divided into two groups by using closed envelope method. postoperative pain scores at rest at 1, 2, 4, 6, 8, 10, 12, and 24 hours with vas (0 = no pain, very severe pain = 10) using visual analogue scale was made. vas at rest and movement (coughing and taking a deep breath) were evaluated. patients with vas\> 4 received additional analgesics.

Eligibility criteria:
asa i, ii, iii patients aged 18-65 who consented to undergo unilateral percutaneous nephrolithotomy were eligible for the study. 53 patients were eligible and assesed.informed consent was signed by all patients. patients under 18 years of age, pregnant, with known hypersensitivity to local anesthetics, bleeding diathesis, depression and / or anxiety disorder, obesity (bmi\> 35kg / m2), history of pneumothorax, phrenic nerve paralysis, severe aortic stenosis were excluded. also who did not want to participate the study.

Keywords: pain management analgesia paravertebral block nephrolithotomy